107 related articles for article (PubMed ID: 28595200)
1. [Daptomycin in left-sided endocarditis: A single center experience].
Açar B; Tezer Tekçe Y; Yayla Ç; Ünal S; Ertem AG; Şentürk B; Özcan Çelebi Ö; Aydoğdu S
Turk Kardiyol Dern Ars; 2017 Jun; 45(4):310-315. PubMed ID: 28595200
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Gram-positive left-sided infective endocarditis with daptomycin.
Kaya S; Yilmaz G; Kalkan A; Ertunç B; Köksal I
J Infect Chemother; 2013 Aug; 19(4):698-702. PubMed ID: 23299359
[TBL] [Abstract][Full Text] [Related]
3. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.
Carugati M; Bayer AS; Miró JM; Park LP; Guimarães AC; Skoutelis A; Fortes CQ; Durante-Mangoni E; Hannan MM; Nacinovich F; Fernández-Hidalgo N; Grossi P; Tan RS; Holland T; Fowler VG; Corey RG; Chu VH;
Antimicrob Agents Chemother; 2013 Dec; 57(12):6213-22. PubMed ID: 24080644
[TBL] [Abstract][Full Text] [Related]
4. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
Levine DP; Lamp KC
Am J Med; 2007 Oct; 120(10 Suppl 1):S28-33. PubMed ID: 17904948
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin-containing regimens for treatment of Gram-positive endocarditis.
Russo A; Peghin M; Givone F; Ingani M; Graziano E; Bassetti M
Int J Antimicrob Agents; 2019 Oct; 54(4):423-434. PubMed ID: 31400470
[TBL] [Abstract][Full Text] [Related]
6. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of daptomycin in the treatment of enterococcal endocarditis: a 5 year comparison with conventional therapy.
Cerón I; Muñoz P; Marín M; Segado A; Roda J; Valerio M; Bouza E;
J Antimicrob Chemother; 2014 Jun; 69(6):1669-74. PubMed ID: 24532682
[TBL] [Abstract][Full Text] [Related]
8. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis.
Durante-Mangoni E; Casillo R; Bernardo M; Caianiello C; Mattucci I; Pinto D; Agrusta F; Caprioli R; Albisinni R; Ragone E; Utili R
Clin Infect Dis; 2012 Feb; 54(3):347-54. PubMed ID: 22100575
[TBL] [Abstract][Full Text] [Related]
9. Daptomycin for the treatment of infective endocarditis: results from a European registry.
Dohmen PM; Guleri A; Capone A; Utili R; Seaton RA; González-Ramallo VJ; Pathan R; Heep M; Chaves RL
J Antimicrob Chemother; 2013 Apr; 68(4):936-42. PubMed ID: 23190763
[TBL] [Abstract][Full Text] [Related]
10. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
11. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients.
Segreti JA; Crank CW; Finney MS
Pharmacotherapy; 2006 Mar; 26(3):347-52. PubMed ID: 16503714
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
[TBL] [Abstract][Full Text] [Related]
13. Indications for daptomycin use in endocarditis and pacemaker lead infection and outcomes in Leeds, UK.
Sandoe J; Baig W
Future Cardiol; 2012 Jul; 8(4):547-54. PubMed ID: 22871194
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci.
Cervera C; Castañeda X; Pericas JM; Del Río A; de la Maria CG; Mestres C; Falces C; Marco F; Moreno A; Miró JM
Int J Antimicrob Agents; 2011 Nov; 38(5):365-70. PubMed ID: 21420835
[TBL] [Abstract][Full Text] [Related]
15. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.
Kullar R; Casapao AM; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ
J Antimicrob Chemother; 2013 Dec; 68(12):2921-6. PubMed ID: 23928022
[TBL] [Abstract][Full Text] [Related]
16. In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis.
Dortet L; Anguel N; Fortineau N; Richard C; Nordmann P
Int J Infect Dis; 2013 Nov; 17(11):e1076-7. PubMed ID: 23578850
[TBL] [Abstract][Full Text] [Related]
17. Daptomycin and rifampin for the treatment of methicillin-resistant Staphylococcus aureus septic pulmonary emboli in the absence of endocarditis.
Gomez EO; Jafary A; Dever LL
Microb Drug Resist; 2010 Sep; 16(3):241-4. PubMed ID: 20617926
[TBL] [Abstract][Full Text] [Related]
18. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.
Ruggero MA; Peaper DR; Topal JE
Infect Dis (Lond); 2015 Jun; 47(6):379-84. PubMed ID: 25746601
[TBL] [Abstract][Full Text] [Related]
19. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.
Cervera C; Castañeda X; de la Maria CG; del Rio A; Moreno A; Soy D; Pericas JM; Falces C; Armero Y; Almela M; Ninot S; Pare JC; Mestres CA; Gatell JM; Marco F; Miro JM;
Clin Infect Dis; 2014 Jun; 58(12):1668-75. PubMed ID: 24647021
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis.
Mergenhagen KA; Pasko MT
Ann Pharmacother; 2007 Sep; 41(9):1531-5. PubMed ID: 17652126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]